Delving into the Latest Updates on Buprenorphine Hydrochloride with Synapse

Overview

Basic Info

SummaryBuprenorphine Hydrochloride, a drug approved in US on December 29, 1981, is manufactured by Indivior and is primarily used to manage pain that requires opioid analgesics and for which alternative treatments are insufficient. Buprenorphine works as a partial agonist at the mu-opioid receptor and as an antagonist at the kappa-opioid receptor. Its slow rate of dissociation from its receptor, which has been observed in vitro studies, accounts for its longer duration of action compared to morphine, its unpredictability of reversal by opioid antagonists, and its low level of manifest physical dependence. Buprenex is an important drug for pain management and has been widely used in the medical field.

Drug Type

Small molecule drug

Synonyms

BUP-XR, Buprenorphine hydrochloride (JP17/USP), Buprenorphine Transdermal Patch

+ [38]

Target

κ opioid receptor x μ opioid receptor

Action

antagonists, agonists

Mechanism

κ opioid receptor antagonists(Kappa opioid receptor antagonists), μ opioid receptor agonists(Mu opioid receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Opioid abuseChronic PainPain+ [6]

Inactive Indication

Back PainDiabetes Mellitus, Type 2Heroin Dependence+ [12]

Originator Organization

Indivior PLC

Active Organization

L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A.Indivior, Inc.RB Pharmaceuticals Ltd.

+ [7]

Inactive Organization

Purdue Pharma LPNational Institute on Drug Dependence,Peking University

Braeburn, Inc.

+ [11]

License Organization

Purdue Pharma LPL. MOLTENI & C. DEI FRATELLI ALITTI - SOCIETA DI ESERCIZIO - S.P.A.Accord Healthcare, Inc. (Canada)

+ [11]

Drug Highest PhaseApproved

First Approval Date

United States (29 Dec 1981),

Pain

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC29H42ClNO4

InChIKeyUAIXRPCCYXNJMQ-RZIPZOSSSA-N

CAS Registry53152-21-9

The goal of this clinical trial is to learn if buprenorphine can be started for opioid use disorder with fentanyl use without requiring or precipitating opioid withdrawal. To be eligible, participants must have moderate or severe opioid use disorder and must have fentanyl detected on a urine drug test.
Participants will be admitted to a monitored research unit for the trial. They will be randomized to start buprenorphine with either standard initiation or with a new approach called rapid outpatient low-dose initiation (ROLDI).
For standard initiation, participants will be instructed to arrive to the unit with at least 8 hours since last fentanyl use. Once they have at least moderately severe opioid withdrawal (Clinical Opiate Withdrawal Scale [COWS] 11 or higher), participants will receive 2 mg, 2 mg, 4 mg, and then 8 mg sublingual buprenorphine, with doses every 2 hours. They will then continue 8 mg twice daily (or up to three times daily). This is the current standard of care.
For ROLDI, participants will not be required to have a period abstinence, they will have no or minimal withdrawal (COWS 4 or less) when starting buprenorphine, and participants will take 0.5 mg, 0.5 mg, 1 mg, 1 mg, 1 mg, and then 4 mg sublingual buprenorphine with dosing every two hours. They will then continue 8mg twice daily (or up to three times daily).
The main aim of this clinical trial is to assess whether ROLDI is safe, feasible, acceptable to patients, and worthwhile to study in a larger trial. The secondary aim is to describe fentanyl and norfentanyl pharmacokinetics (that is to say, fentanyl and norfentanyl concentration in blood and urine) during early abstinence to understand why some people using fentanyl develop precipitated withdrawal with standard initiation.

Start Date08 May 2025

Sponsor / Collaborator

University of Pennsylvania

[+1]

CTRI/2025/04/084623

/ Not yet recruitingPhase 2/3IIT

A Prospective study to compare epidural buprenorphine versus epidural tramadol for post operative analgesia in lower limb orthopedic replacement surgeries. - nil

Start Date21 Apr 2025

Sponsor / Collaborator-

100 Clinical Results associated with Buprenorphine Hydrochloride

Login to view more data

100 Translational Medicine associated with Buprenorphine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Buprenorphine Hydrochloride

Login to view more data

6,140

Literatures (Medical) associated with Buprenorphine Hydrochloride

01 Oct 2025·COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY

Effects of re-enter water on antioxidant, immune, intestinal flora and metabolome of Chinese mitten crab (Eriocheir sinensis) after high temperature air exposure

Article

Author: Wang, Shihui ; Luo, Liang ; Yang, Yuhong ; Li, Zhiqiang ; Zhao, Zhigang ; Guo, Kun ; Zhang, Rui ; Deng, Xiangyi

Both air exposure stress and heat stress can cause stress responses of Eriocheir sinensis and affect its normal life activities. The objective of this research was to investigate the impact of re-enter water treatment on immunoenzyme activity, immune-related gene expression, hemolymph parameters, intestinal microbiota composition, and metabolomic profiles in Eriocheir sinensis after being subjected to high-temperature air exposure. The findings indicated that the re-enter water effectively mitigated the negative impacts of high-temperature air exposure on both antioxidant and immune capacities. Following treatment with high-temperature air, levels of acid phosphatase (ACP), alkaline phosphatase (AKP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were significantly elevated compared to their baseline values (P < 0.05), followed by a decline as re-enter water started with recovery to baseline levels detected at 24 h after re-enter water. Additionally, the levels of heat shock proteins HSP90 and HSP70 exhibited a notable rise after being subjected to high-temperature air. Nevertheless, after 24 h of soaking treatment, these levels reverted to values similar to those recorded initially. However, after re-enter water treatment, the changes in intestinal microbial composition and metabolic level caused by high temperature air exposure were not effectively improved. The analysis of intestinal microbiota revealed that the relative abundance of Bacteroidetes in the recovery group was significantly lower compared to the initial group, whereas the relative abundances of Proteobacteria and Firmicutes were found to be higher than those in the initial group. Concurrently, metabolomics analysis indicated a significant increase in palmitic acid metabolism levels within the high-temperature air group (P < 0.05), while glycine content showed a notable decrease (P < 0.05), and the metabolic changes caused by high temperature air exposure was still not fully recovered after re-enter water.

01 Sep 2025·WATER RESEARCH

Estimating the consumption of prescription opioids through wastewater analysis: The patterns of use in Italy

Article

Author: de Voogt, Pim ; Béen, Frederic ; Castiglioni, Sara ; van Nuijs, Alexander L N ; Zuccato, Ettore ; Corli, Oscar ; Hernández, Félix ; Matias, João ; Bijlsma, Lubertus ; Salgueiro-Gonzalez, Noelia ; Boogaerts, Tim ; Kasprzyk-Hordern, Barbara

Prescription opioids have recently experienced a diversion of use in several countries causing a huge number of overdoses due to their high potency. The aim of this study was to develop a wastewater-based epidemiology (WBE) approach to assess the use of prescription opioids and evaluate the compliance to prescriptions to highlight the potential misuse of these substances in Italy. The most prescribed opioids have been selected and validated as WBE biomarkers and a nation-wide study has been conducted over a three-year period (2020-2022). Wastewater (WW) samples were collected as 24-hour composite samples in eight Italian cities and parent substances or metabolites were quantified using validated analytical methods based on liquid chromatography - tandem mass spectrometry (LC-MS/MS). Daily loads have been normalized to therapeutic doses to obtain a real figure of use that showed higher use of tapentadol and morphine compared to oxycodone and fentanyl. Back-calculation of consumption estimates was done by using the most reliable WBE biomarkers and were compared with prescription data. Spatial and temporal differences were found and highlighted a lower use in the south compared to the north and the center of Italy. Data comparison with prescriptions gave results in the same range indicating that the use of these substances in Italy seems to be predominantly from prescription for therapeutic purposes. This study highlighted the suitability of WBE to investigate the potential non-medical use of prescription pharmaceuticals in a population, providing relevant information for supporting public health emergencies and policies.

01 Sep 2025·Drug and alcohol dependence reports

Factors associated with emergency room visits among patients with opioid use disorder: A study of buprenorphine-treated and untreated patients

Article

Author: Gu, Yifan ; Wheeler, Ann ; Dunne, Robert ; DeKoven, Mitch ; Munnangi, Swapna ; Mullen, William ; Gaiazov, Sabrina

Objective:

Identify factors associated with 6-month emergency room (ER) outcomes in patients with opioid use disorder (OUD) and/or treated with buprenorphine (extended-release [BUP-XR] or transmucosal [BUP-TM]). Compare baseline characteristics and 6-month ER visits and healthcare resource utilization (HCRU) across treatment groups.

Methods:

Patient claims data from September 2017- March 2022 were analyzed for patients diagnosed with OUD and/or treated with buprenorphine. Adjusted logistic regression models were used to identify factors associated with ER visits 6-months post-index.

Results:

543 patients initiating BUP-XR, 52,569 BUP-TM and 57,125 patients with OUD diagnosis but no-medications for opioid use disorder (MOUD) were identified.Patients who received BUP-XR (OR: 0.43, 95 % CI: 0.36-0.53) or BUP-TM (OR: 0.78; CI: 0.76-0.81) had lower odds for an all-cause post-index ER visit compared to those with no MOUD treatment.Patients with later index years or those who had an opioid overdose ER visit in the baseline period had higher odds of post-index all-cause and opioid overdose ER visits.1.2 % in BUP-TM cohort and 1 % in the no MOUD cohort had an opioid overdose ER visit, compared to 0 % in the BUP-XR cohort. The BUP-XR cohort had lower rates of inpatient stays, ER visits, and outpatient physician office visits compared to the BUP-TM and no MOUD cohorts but incurred higher pharmacy costs.

Conclusions:

This study found that any buprenorphine treatment, particularly BUP-XR, was associated with lower odds of all-cause ER visits compared to patients with no MOUD, and highlighted potential risk factors that could help reduce the demand on ER services.

328

News (Medical) associated with Buprenorphine Hydrochloride

23 Jul 2025

·www.prnewswire.com

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician oﬃce visits compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD) The study indicates BUP-XR may be an important tool in reducing ED visits, improving healthcare resource utilization and patient outcomes RICHMOND, Va., July 23, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports, which examined demographic and clinical factors associated with ED visits among adults diagnosed with opioid use disorder (OUD) over a six-month follow-up period. The study found that patients treated with BUP-XR, in the form of the once-monthly long-acting injectable formulation of buprenorphine, had 57% lower odds of all-cause ED visits compared to those who received no MOUD. Additionally, patients treated with BUP-XR experienced signiﬁcantly fewer hospitalizations and lower inpatient costs compared to those receiving daily oral buprenorphine or no MOUD. "Opioid overdose-related ED visits are a critical concern in the ongoing opioid epidemic," said Christian Heidbreder, Ph.D., Chief Scientiﬁc Oﬃcer at Indivior. "These ﬁndings underscore the clinical and economic value of long-acting injectable treatments of OUD. By reducing ED and physician oﬃce visits, BUP-XR may help ease the burden on our healthcare system while supporting long-term recovery outcomes for patients." The Indivior-funded study also revealed that patients treated with BUP-XR incurred lower inpatient healthcare costs. Inpatient costs for this group were nearly ﬁve times lower compared to patients receiving daily oral buprenorphine, and more than 10 times lower compared to patients receiving no MOUD. The BUP-XR cohort did have similar overall all-cause costs compared to the no MOUD cohort and had signiﬁcantly higher overall costs compared to the daily oral buprenorphine cohort; this was primarily driven by higher outpatient pharmacy costs in the BUP-XR cohort, although it was not possible to determine if the BUP-XR medication itself was driving the diﬀerence. Hospitalization rates for BUP-XR were similarly lower: only 3% of BUP-XR-treated patients experienced an inpatient stay during the six-month follow-up period, versus 5% of those on daily oral buprenorphine. Notably, no opioid overdose-related ED visits were recorded among patients in the BUP-XR cohort during the study period; in the daily oral buprenorphine cohort there was a 1.2% overdose rate and 1% in the no MOUD cohort. These ﬁndings are based on observed claims data and reﬂect healthcare utilization during the deﬁned study period. Although the results oﬀer valuable insights for public health oﬃcials, emergency care providers, and policymakers, the study sample may not fully represent all individuals with OUD, particularly those who are uninsured or outside traditional healthcare systems. Additionally, the six-month observation window may not capture long-term treatment engagement or relapse risk. The full study is available here: Factors associated with emergency room visits among patients with opioid use disorder: A study of buprenorphine-treated and untreated patients - ScienceDirect Disclosure: This press release has been issued by Indivior Inc. and the content has not been approved or authorized by the College on Problems of Drug Dependence. About SUBLOCADE® SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. HIGHLIGHTED SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body ﬂuids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self- administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certiﬁed in this program and comply with the REMS requirements. CONTRAINDICATIONS Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis. Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. Adrenal Insuﬃciency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient oﬀ of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately. Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment. Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE. Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic eﬀect. ADVERSE REACTIONS Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain. For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit . About Opioid Use Disorder (OUD) Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may aﬀect the parts of the brain that are necessary for life-sustaining functions. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting . SOURCE Indivior PLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

12 May 2025

·www.globenewswire.com

Porch Light Health Acquires Comprehensive Behavioral Health Center to Expand Access to Full-Spectrum Addiction Treatment

DENVER, May 12, 2025 (GLOBE NEWSWIRE) -- Porch Light Health, the largest addiction medicine practice in Colorado, offering outpatient Medications for Addiction Treatment (MAT) at more than 60 treatment locations, is proud to announce the acquisition of Comprehensive Behavioral Health Center (CBHC), a respected Opioid Treatment Program (OTP) provider with clinics in Denver and Lakewood, Colorado. This strategic partnership marks a pivotal step in advancing Porch Light Health’s mission to broaden access to high-quality, patient-centered care for individuals living with opioid use disorder through evidence-based treatment solutions. By adding OTP services, Porch Light Health will now offer the full spectrum of MAT options—including buprenorphine, methadone and naltrexone—ensuring that patients receive the most appropriate treatment for their unique needs. “In combining our strengths with CBHC, we are deepening our impact to create an even more integrated care environment that prioritizes access, innovation and recovery for every individual seeking treatment, ” said Doug Weiss, MBA, Chief Executive Officer at Porch Light Health. While day-to-day operations will remain largely unchanged, the collaboration presents expanded opportunities to experience life beyond addiction. “This is a significant step forward in breaking down long-standing barriers in addiction medicine,” said Joy Mercer, BA and CAS, Program Director at CBHC. “This comprehensive approach is a win-win. We reaffirm that there is no ‘one-size-fits-all’ approach to recovery. Through Porch Light Health, our patients will now have access to additional services, including psychiatric medicine management, behavioral health care, infectious disease treatment and more.” Together, Porch Light Health and CBHC will continue to challenge stigma, innovate care delivery and empower individuals on the path to recovery. About Porch Light Health Porch Light Health’s mission (formerly Front Range Clinic), is to provide low-barrier, high-access, quality medical addiction treatment to those affected by substance use disorders and related medical conditions. Porch Light Health offers comprehensive outpatient addiction medicine treatment service for alcohol and drug use disorders, including Opioids, Stimulants and Sedatives, as well as nicotine and cannabis use. In addition to evidence-based medical treatment, PLH offers psychiatry and therapy services, including treatment of infectious disease and other comorbidities. Media Contact:Dayle Cedars303-907-3698daylecedars@gmail.com https://porchlighthealth.com

Acquisition

12 May 2025

·www.einpresswire.com

Porch Light Health Acquires Comprehensive Behavioral Health Center to Expand Access to Full-Spectrum Addiction Treatment

DENVER, May 12, 2025 (GLOBE NEWSWIRE) -- Porch Light Health, the largest addiction medicine practice in Colorado, offering outpatient Medications for Addiction Treatment (MAT) at more than 60 treatment locations, is proud to announce the acquisition of Comprehensive Behavioral Health Center (CBHC), a respected Opioid Treatment Program (OTP) provider with clinics in Denver and Lakewood, Colorado. This strategic partnership marks a pivotal step in advancing Porch Light Health’s mission to broaden access to high-quality, patient-centered care for individuals living with opioid use disorder through evidence-based treatment solutions. By adding OTP services, Porch Light Health will now offer the full spectrum of MAT options—including buprenorphine, methadone and naltrexone—ensuring that patients receive the most appropriate treatment for their unique needs. “In combining our strengths with CBHC, we are deepening our impact to create an even more integrated care environment that prioritizes access, innovation and recovery for every individual seeking treatment, ” said Doug Weiss, MBA, Chief Executive Officer at Porch Light Health. While day-to-day operations will remain largely unchanged, the collaboration presents expanded opportunities to experience life beyond addiction. “This is a significant step forward in breaking down long-standing barriers in addiction medicine,” said Joy Mercer, BA and CAS, Program Director at CBHC. “This comprehensive approach is a win-win. We reaffirm that there is no ‘one-size-fits-all’ approach to recovery. Through Porch Light Health, our patients will now have access to additional services, including psychiatric medicine management, behavioral health care, infectious disease treatment and more.” Together, Porch Light Health and CBHC will continue to challenge stigma, innovate care delivery and empower individuals on the path to recovery. About Porch Light Health Porch Light Health’s mission (formerly Front Range Clinic), is to provide low-barrier, high-access, quality medical addiction treatment to those affected by substance use disorders and related medical conditions. Porch Light Health offers comprehensive outpatient addiction medicine treatment service for alcohol and drug use disorders, including Opioids, Stimulants and Sedatives, as well as nicotine and cannabis use. In addition to evidence-based medical treatment, PLH offers psychiatry and therapy services, including treatment of infectious disease and other comorbidities. Media Contact: Dayle Cedars 303-907-3698 daylecedars@gmail.com https://porchlighthealth.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Acquisition

100 Deals associated with Buprenorphine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00836	Buprenorphine Hydrochloride	N07BC01 N02AE01	DB00921

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Opioid abuse	Canada	Knight Therapeutics, Inc.	18 Apr 2018
Chronic Pain	Canada	Paladin Labs, Inc.	21 Jun 2017
Opium Dependence	Belgium	RB Pharmaceuticals Ltd.	02 Nov 1999
Opium Dependence	Cyprus	RB Pharmaceuticals Ltd.	02 Nov 1999
Opium Dependence	Czechia	RB Pharmaceuticals Ltd.	02 Nov 1999
Opium Dependence	France	RB Pharmaceuticals Ltd.	02 Nov 1999
Opium Dependence	Latvia	RB Pharmaceuticals Ltd.	02 Nov 1999
Opium Dependence	Lithuania	RB Pharmaceuticals Ltd.	02 Nov 1999
Opium Dependence	Luxembourg	RB Pharmaceuticals Ltd.	02 Nov 1999
Opium Dependence	Portugal	RB Pharmaceuticals Ltd.	02 Nov 1999
Substance-Related Disorders	China	QingHai Pharm	01 Jan 1994
Anesthesia	Japan	Otsuka Pharmaceutical Co., Ltd.	27 May 1983
Cancer Pain	Japan	Otsuka Pharmaceutical Co., Ltd.	27 May 1983
Pain, Postoperative	Japan	Otsuka Pharmaceutical Co., Ltd.	27 May 1983
Pain	United States	Indivior, Inc.	29 Dec 1981

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neuralgia	Phase 3	United States	BioDelivery Sciences International, Inc.	01 Mar 2011
Intervertebral Disc Disease	Phase 3	China	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Aug 2009
Heroin Dependence	Phase 3	United States	Indivior, Inc.	01 May 2009
opioid dependence methadone	Phase 3	United States	Titan Pharmaceuticals, Inc.	01 Oct 2006
Low Back Pain	Phase 3	Japan	Mundipharma KK	01 May 2006
Osteoarthritis, Spine	Phase 3	United States	Purdue Pharma LP	01 Jan 2004
Opioid-Related Disorders	Phase 3	United States	University of California, Los Angeles	01 Jun 2003
Diabetes Mellitus, Type 2	Phase 3	United States	Purdue Pharma LP	01 Apr 2003
Osteoarthritis	Phase 3	United States	Purdue Pharma LP	01 Apr 2003
Pain Disorder	Phase 3	United States	Purdue Pharma LP	01 Mar 2001

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PRNewswire \| Pubmed Manual	Not Applicable	Opioid-Related Disorders	322	Monthly SUBLOCADE	atkyofetlp(vdgcwevmjg) = xwzddocfta qwytonvwkn (kjsrwpkxmp )	Positive	01 May 2025
NCT05283304 (CTN-0110, CTgov)	Phase 2	Methamphetamine abuse \| Methamphetamine dependence	18	Buprenorphine injection (BUP-Inj) (Injectable Buprenorphine (BUP-inj))	jixcnhctty = jqkluacnru mzibvwwcvc (hviwrcokgo, lyhzjyxykg - gvalmkpzen) View more	-	21 Mar 2025
				Placebo injection (Injectable Placebo (PBO-inj))	jixcnhctty = siwuioatdu mzibvwwcvc (hviwrcokgo, ikkwwqwsaf - nfpijggold) View more
NCT03150173 (O-BMT, CTgov)	Phase 2	Opioid abuse \| Unspecified drug dependence	97	Buprenorphine+Onsite treatment (O-BMT (Onsite Treatment))	usrukuqooo = sshosaizyu jlgxgrjyoq (pwwbolblgl, umugfrhaxw - libjzdbytd) View more	-	14 Jan 2025
				Buprenorphine+Enhanced referral (Enhanced Referral)	usrukuqooo = bhqpbexksb jlgxgrjyoq (pwwbolblgl, gbhccjzjyt - cwjrubpvog) View more
NCT04571619 (HOPE, CTgov)	Phase 2	Opium Dependence \| Kidney Failure, Chronic \| Chronic Pain	643	Buprenorphine+Pain Coping Skills Training (PCST) (Pain Coping Skills Training)	spqntdoyku(vrxuzteigr) = shmceecodt quqygzvvdo (tozcqwcval, 2.02) View more	-	13 Jan 2025
				Buprenorphine (Usual Care)	spqntdoyku(vrxuzteigr) = dfyydndrfq quqygzvvdo (tozcqwcval, 2.13) View more
NCT05704543 (CTgov)	Phase 4	Opioid abuse	132	Buprenorphine Extended-Release Injection (Extended-release Buprenorphine: Abdomen)	qpyfhnmwjw(kbtcvanpvg) = wzwbokbsxj izznbvbmwj (oiyvbunrcu, 41.8) View more	-	07 Jan 2025
				Buprenorphine Extended-Release Injection (Extended-release Buprenorphine: Upper Arm)	qpyfhnmwjw(kbtcvanpvg) = kldsorvzmo izznbvbmwj (oiyvbunrcu, 57.4) View more
NCT04981678 (CTgov)	Phase 4	Opioid-Related Disorders \| Pain \| Opioid abuse	12	Buprenorphine (Buprenorphine Dose Reduction)	nrrldygggo(txoaubxqgj) = aefjchwogx jczjfjvyaz (sialgtxugb, 1.5) View more	-	13 Dec 2024
				Buprenorphine (Buprenorphine Full Dose Continuation)	nrrldygggo(txoaubxqgj) = ircuenepcl jczjfjvyaz (sialgtxugb, 2.4) View more
NCT03605342 (CTgov)	Phase 2	Opioid abuse \| Stress Disorders, Post-Traumatic	38	Buprenorphine+Cognitive Processing Therapy (CPT) (Buprenorphine + CPT-C)	cybnsnnpkv(ekkpsrejtr) = yzgeahfojc atvryyaztq (uidymgfonf, 2.62) View more	-	19 Aug 2024
				Individual Drug Counseling (IDC)+Buprenorphine (Buprenorphine + IDC)	cybnsnnpkv(ekkpsrejtr) = iljpivwzol atvryyaztq (uidymgfonf, 2.76) View more
NCT04254081 (ABCD&E, CTgov)	Phase 4	Anesthesia \| Pain, Procedural	57	Buprenorphine 0.15 MG (Buprenorphine 0.15mg + 1% Lidocaine Paracervical Block)	acxknsippu(usdpgrbrva) = ktqxptofho uallxztdpl (cvhxkovxqg, mkkejrsdcx - ilqsqbawxy) View more	-	01 Aug 2023
				Lidocaine 1% Injectable Solution (1% Lidocaine Paracervical Block)	acxknsippu(usdpgrbrva) = rfeuflakui uallxztdpl (cvhxkovxqg, fgranwivpi - zxkueqocbv) View more
NCT03852628 (CTgov)	Phase 2	Alcoholism \| Stress Disorders, Post-Traumatic	69	2mg Buprenex+380mg Vivitrol (2mg Buprenex and 380mg Vivitrol)	olcyakqyum = efymvpcxwe rusozlenwh (rhxpmgflbe, iejvczfold - ybtcibujpe) View more	-	07 Jun 2023
				Placebo (SL pill qd, IM injection q4weeks) (Placebo)	olcyakqyum = ysznswodbl rusozlenwh (rhxpmgflbe, wvudlcccvd - jjkbnfnlsu) View more
NCT02187198 (CTgov)	Phase 3	Opium Dependence	9	Buprenorphine (Buprenorphine Low Dose)	cbfxthnlmp = axnbdpocyj ojcvhqgobc (neudnaipbc, tmxklxefay - xbilntkgnq) View more	-	10 Mar 2023
				Buprenorphine (Buprenorphine High Dose)	cbfxthnlmp = qncbvkitzs ojcvhqgobc (neudnaipbc, gtfoithana - vigqtzdfoa) View more